©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 27, 2015; 7(1): 121-126
Published online Jan 27, 2015. doi: 10.4254/wjh.v7.i1.121
Published online Jan 27, 2015. doi: 10.4254/wjh.v7.i1.121
HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches
Mohammad Khalid Parvez, Department of Pharmacognosy, King Saud University College of Pharmacy, Riyadh 11451, Saudi Arabia
Author contributions: The author contributed solely to this work.
Correspondence to: Mohammad Khalid Parvez, PhD, Assistant Professor, Department of Pharmacognosy, King Saud University College of Pharmacy, PO Box 2457, Riyadh 11451, Saudi Arabia. khalid_parvez@yahoo.com
Telephone: +966-1-4675132 Fax: +966-1-4677254
Received: July 16, 2014
Peer-review started: July 17, 2014
First decision: July 29, 2014
Revised: August 15, 2014
Accepted: November 7, 2014
Article in press: November 10, 2014
Published online: January 27, 2015
Processing time: 177 Days and 21.2 Hours
Peer-review started: July 17, 2014
First decision: July 29, 2014
Revised: August 15, 2014
Accepted: November 7, 2014
Article in press: November 10, 2014
Published online: January 27, 2015
Processing time: 177 Days and 21.2 Hours
Core Tip
Core tip: The consequences of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) co-infection on progression of severe liver diseases is a serious public health issue, worldwide. In HIV co-infected individuals, liver-related mortality is estimated over 17 times higher than those with HBV mono-infection. HIV co-infection significantly alters the natural history of hepatitis B, and therefore complicates the disease management. Thus, the clinical spectrum as well as the complexity of the HBV and HIV co-infection of liver offers challenging fronts to study the underlying molecular mechanisms, and to design effective therapeutic strategies.